Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BOLD vs. BMEA, BNTC, NGNE, SLN, ZNTL, TRVI, AMRN, CRBP, ACRV, and XBITShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Biomea Fusion (BMEA), Benitec Biopharma (BNTC), Neurogene (NGNE), Silence Therapeutics (SLN), Zentalis Pharmaceuticals (ZNTL), Trevi Therapeutics (TRVI), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Acrivon Therapeutics (ACRV), and XBiotech (XBIT). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. Biomea Fusion Benitec Biopharma Neurogene Silence Therapeutics Zentalis Pharmaceuticals Trevi Therapeutics Amarin Corbus Pharmaceuticals Acrivon Therapeutics XBiotech Biomea Fusion (NASDAQ:BMEA) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Does the MarketBeat Community believe in BMEA or BOLD? Audentes Therapeutics received 419 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 69.22% of users gave Audentes Therapeutics an outperform vote while only 66.23% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes5166.23% Underperform Votes2633.77% Audentes TherapeuticsOutperform Votes47069.22% Underperform Votes20930.78% Is BMEA or BOLD more profitable? Biomea Fusion's return on equity of -118.90% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Audentes Therapeutics N/A -321.10%-40.02% Does the media refer more to BMEA or BOLD? In the previous week, Biomea Fusion had 3 more articles in the media than Audentes Therapeutics. MarketBeat recorded 3 mentions for Biomea Fusion and 0 mentions for Audentes Therapeutics. Biomea Fusion's average media sentiment score of 0.20 beat Audentes Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media. Company Overall Sentiment Biomea Fusion Neutral Audentes Therapeutics Neutral Which has better valuation and earnings, BMEA or BOLD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-1.61Audentes TherapeuticsN/AN/A-$49.43MN/AN/A Do insiders and institutionals hold more shares of BMEA or BOLD? 96.7% of Biomea Fusion shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Comparatively, 5.3% of Audentes Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate BMEA or BOLD? Biomea Fusion currently has a consensus price target of $30.50, indicating a potential upside of 371.41%. Audentes Therapeutics has a consensus price target of $23.00, indicating a potential upside of 748.71%. Given Audentes Therapeutics' higher probable upside, analysts clearly believe Audentes Therapeutics is more favorable than Biomea Fusion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00Audentes Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBiomea Fusion beats Audentes Therapeutics on 7 of the 12 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.43M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5695.6214.26Price / SalesN/A371.591,217.1987.73Price / CashN/A52.5939.5936.27Price / Book0.3710.236.946.36Net Income-$49.43M$153.22M$118.89M$225.56M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics2.4902 of 5 stars$2.71+0.7%$23.00+748.7%N/A$60.43MN/A0.00207BMEABiomea Fusion3.441 of 5 stars$6.47+3.0%$30.50+371.4%-39.1%$234.47MN/A-1.5750Analyst ForecastBNTCBenitec Biopharma2.3119 of 5 stars$10.03-5.9%$22.60+125.3%+202.8%$232.90M$80,000.000.0020Positive NewsGap DownNGNENeurogene2.9353 of 5 stars$15.50+1.1%$60.83+292.5%N/A$230.18MN/A0.0090Analyst ForecastAnalyst RevisionNews CoverageSLNSilence Therapeutics3.6582 of 5 stars$7.58+9.4%$57.20+654.6%-27.1%$226.87M$31.55M0.00100Analyst ForecastNews CoverageHigh Trading VolumeZNTLZentalis Pharmaceuticals2.6036 of 5 stars$3.16+1.0%$10.00+216.5%-71.1%$225.18MN/A0.00160Analyst RevisionTRVITrevi Therapeutics3.4256 of 5 stars$2.76-0.4%$7.43+169.2%+113.1%$212.16MN/A-6.3020AMRNAmarin0.1419 of 5 stars$0.51+2.9%N/A-37.4%$208.95M$306.91M0.00360CRBPCorbus Pharmaceuticals4.8796 of 5 stars$16.78+4.4%$65.86+292.5%+249.6%$204.38M$880,000.00-3.4840Positive NewsACRVAcrivon Therapeutics2.7542 of 5 stars$6.55+0.8%$23.67+261.3%+62.9%$203.97MN/A0.0058Analyst RevisionXBITXBiotech0.8966 of 5 stars$6.64+2.3%N/A+77.8%$202.39M$4.01M-6.01100Positive News Related Companies and Tools Related Companies Biomea Fusion Competitors Benitec Biopharma Competitors Neurogene Competitors Silence Therapeutics Competitors Zentalis Pharmaceuticals Competitors Trevi Therapeutics Competitors Amarin Competitors Corbus Pharmaceuticals Competitors Acrivon Therapeutics Competitors XBiotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
